Aspire Biopharma has entered a strategic partnership with Microsize to advance the development of a new sublingual powder formulation of alprazolam, targeting rapid anxiety relief.
Esperion Therapeutics has signed a definitive agreement to acquire Corstasis Therapeutics to expand its cardiovascular franchise with the addition of Enbumyst, a bumetanide nasal spray.
US-based biotechnology company Rallybio has entered a definitive agreement to acquire Candid Therapeutics through a merger transaction.
Kairos Pharma has signed a binding agreement to acquire exclusive worldwide rights to CL-273 from Celyn Therapeutics, a company backed by OrbiMed and Torrey Pines Investment.
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Sanofi and Regeneron’s Dupixent (dupilumab) in the European Union (EU) for paediatric patients with chronic spontaneous urticaria (CSU).
BioMarin Pharmaceutical has received the US Food and Drug Administration (FDA) approval for its supplemental biologics licence application (sBLA) for Palynziq’s (pegvaliase-pqpz) use in adolescents aged 12 and above with phenylketonuria (PKU).
Asahi Kasei has signed a definitive agreement to acquire all issued shares of German-based Aicuris Anti-infective Cures for approximately €780m ($920.7m).
IQVIA Holdings has signed an agreement to acquire selected discovery service assets from Charles River Laboratories, aiming to expand its end-to-end capabilities.
Novo Nordisk and Vivtex have entered a partnership focused on developing next-generation oral biologic therapies to treat obesity, diabetes and related comorbidities.
Slate Medicines has secured a $130m Series A financing round aimed at advancing anti-pituitary adenylate cyclase-activating polypeptide (PACAP) migraine therapies.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.